Breakthrough pain: On the road again

European Journal of Pain

Volumn 13, Issue 4, 2009, Pages 329-330

  Mercadante, Sebastiano ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE; OPIATE;

ANALGESIA; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; PAIN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANALGESIA; ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PAIN, INTRACTABLE; RECEPTORS, OPIOID; SELF ADMINISTRATION;

EID: 61849104592     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2008.11.021     Document Type: Editorial

References (14)

1. Christie J., Simmonds M., Patt R., Coluzzi P., Busch M., Nordbrock E., et al. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16 (1998) 3238-3245
2. Coluzzi P., Schwartzberg L., Conroy J., Chaparata S., Gay M., Busch M., et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 91 (2001) 123-130
3. Davies A., Dickman A., Reid C., Stevens A., and Zeppetella J. The management of cancer-related breakthrough pain: recommendations of a task group of the Association of palliative medicine of Great Britain and Ireland. Eur J Pain 13 (2009) 330-337
4. Davies A.N., Vriens J., Kennett A., and McTaggart M. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 35 (2008) 406-411
5. Farrar J., Cleary J., Rauck R., Busch M., and Nordbrock E. Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90 (1998) 611-616
6. Hagen N.A., Fisher K., Victorino C., and Farrar J.T. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10 (2007) 47-55
7. Hanks G.W., De Conno F., Cherny N., Hanna M., Kalso E., McQuay H.J., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Brit J Cancer 84 (2001) 587-593
8. Mercadante S., Radbruck L., Caraceni A., Cherny N., Kaasa S., Nauck F., et al. Episodic (breakthrough pain) consensus conference of an expert working group of the European Association of Palliative Care. Cancer 94 (2002) 832-839
9. Mercadante S., Villari P., Ferrera P., Bianchi M., and Casuccio A. Safety and effectiveness of intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 27 (2004) 352-359
10. Mercadante S., Villari P., Ferrera P., Casuccio A., Mangione S., and Intravaia G. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Brit J Cancer 96 (2007) 1828-1833
11. Mercadante S., Intravaia G., Villari P., Ferrera P., Riina S., and Mangione S. Intravenous morphine for breakthrough (episodic) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 35 (2008) 307-313
12. Portenoy R.K., and Hagen N.A. Breakthrough pain: definition, prevalence and characteristics. Pain 41 (1990) 273-281
13. Portenoy R.K., Payne R., Coluzzi P., et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79 (1999) 303-312
14. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 35 (2008) 563-567